[Elsevier] Optimizing management of cutaneous toxicities from amivantamab in first-line non-small cell lung cancer: A clinical perspective

maryamawadhpdc Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-07-30 06:33
Reward20points

journalㄩCritical Reviews in Oncology/Hematology

AuthorsㄩIlaria Attili; Giulio Tosti; Francesca Pepe; Antonio Passaro; Filippo de Marinis

Published dateㄩ2025-11-

DOIㄩ10.1016/j.critrevonc.2025.104926

PDF linkㄩhttps://www.sciencedirect.com/sc ... 040842825003142/pdf

Article linkㄩhttps://doi.org/10.1016/j.critrevonc.2025.104926

Article SourceㄩElsevier BV


Remarkㄩ

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
mohamedehab Post time 1 hour(s) ago | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    0


Return to the list